The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.
Consumer medical products maker Compass Health Brands is voluntarily recalling about 104,900 of its bed rails after receiving reports of three deaths associated with some of the products, the U.S. Consumer Product Safety Commission (CPSC) said on Wednesday.
(Reuters) -Biogen Inc on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.
Health insurance costs for employers rose the most in over a decade this year as Americans resumed non-urgent procedures delayed earlier due to the COVID-19 pandemic, according to a survey published on Monday.
Dec 6 Biohaven Pharmaceutical's
intranasal spray to treat migraine helped relieve pain in as
early as 15 minutes and met the main goals in a late-stage
study, paving the way for the company to file for approval in
the United States next year.
(Reuters) -Cigna Corp on Thursday joined rival U.S. health insurers in signaling a lower hit from costs related to COVID-19 next year and maintained its target of at least 10% earnings growth over a newly raised 2021 adjusted profit estimate.
(Reuters) -CVS Health Corp on Wednesday said its adjusted profit target for 2022 should largely meet Wall Street estimates, as it expects volatile medical costs in its health insurance unit to stabilize after the COVID-19 crisis drove them up this year.
Thermo Fisher Scientific Inc's third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said.
(Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments.
Oct 19 Canadian National Railway (CN)
said on Tuesday Chief Executive Officer Jean-Jacques Ruest will
retire at the end of January, following investor demands for his
exit after the railroad operator's failed bid for Kansas City